The overall agreement includes licensing of a lead, potential first-in-class preclinical candidate, as well as a research collaboration to jointly generate additional novel candidates.
These candidates include previously undisclosed multi-specific fusion protein-based therapeutic candidates for autoimmune and inflammatory diseases.
Under the terms of the agreement, Horizon will make an upfront payment to Alpine of USD 25m as well as an equity investment in Alpine of USD 15m at a 25 % premium to the 30-day volume-weighted average share price.
In addition, Alpine is eligible to receive up to USD 381m per program, or approximately USD 1.52bn in total, in future success-based payments related to development, regulatory and commercial milestones as well as tiered royalties on global net sales.
Under the agreement, Alpine will advance candidate molecules to pre-defined preclinical milestones. Horizon will then assume responsibility for development and commercialization activities and costs.
Similar to changes at other peer companies, beginning in 4Q21, Horizon will no longer exclude upfront and milestone payments related to collaboration and license agreements from non-GAAP R and D expense, adjusted EBITDA and other non-GAAP financial measures and has filed a form 8-K TODAY with additional details.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
Alpine has entered into strategic collaborations with global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.
Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial